BMJ

Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): Randomised, double blind, multicentre, phase 3 trial

ESMO Congress 2023 Abstract

386MO Trastuzumab duocarmazine versus physician's choice therapy in pre-treated HER2-positive metastatic breast cancer: Final results of the phase III TULIP trial

Current Treatment Options in Oncology

Anti-HER2 drugs for the treatment of advanced HER2 positive breast cancer

JAMA Oncology

Pertuzumab plus trastuzumab with or without chemotherapy followed by emtansine in ERBB2-positive metastatic breast cancer

OncLive

Frontline zanidatamab plus docetaxel yields antitumor activity, safety in advanced HER2+ breast cancer

Targeted Oncology

Tucatinib plus T-DM1 lowers risk of progression or death in HER2+ mBC

Clinical Breast Cancer

Long term follow-up of the randomized MetaspHER study comparing intravenous versus subcutaneous trastuzumab in patients with HER2-positive metastatic breast cancer

ESMO Open

Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure

Scientific Reports

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression

2023 ASCO Annual Meeting Abstract

Real-world patient characteristics and treatment patterns associated with tucatinib therapy in patients with HER2+ metastatic breast cancer